Review Article

Mitral Valve Surgery in Patients with Systemic Lupus Erythematosus

Mahnoosh Foroughi, Manouchehr Hekmat, Mohsen Ghorbani, Hamid Ghaderi, Masoud Majidi, and Mahmood Beheshti

Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Modarres Hospital, Saadat Abad, Tehran 19987 34383, Iran

Correspondence should be addressed to Mahnoosh Foroughi; m_foroughi@sbmu.ac.ir

Received 30 June 2014; Accepted 5 August 2014; Published 14 October 2014

Academic Editor: Yehuda Shoenfeld

Copyright © 2014 Mahnoosh Foroughi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Valvular heart disease is the common cardiac manifestation of systemic lupus erythematosus (SLE) with a tendency for mitral valve regurgitation. In this study we report a case of mitral valve replacement for mitral stenosis caused by Libman-Sacks endocarditis in the setting of SLE. In addition, we provide a systematic review of the literature on mitral valve surgery in the presence of Libman-Sacks endocarditis because its challenge on surgical options continues. Surgical decision depends on structural involvement of mitral valve and presence of active lupus nephritis and antiphospholipid antibody syndrome. Review of the literature has also shown that outcome is good in most SLE patients who have undergone valvular surgery, but association of antiphospholipid antibody syndrome with SLE has negative impact on the outcome.

1. Introduction

Most parts of the heart may be affected in the course of systemic lupus erythematosus (SLE): coronary arteries, valves, conduction system, pericardium, myocardium, and endocardium, with a variety of clinical manifestations, and it is the main cause of morbidity and mortality in these patients [1–3]. Valvular involvement is the frequent cardiac manifestation in SLE. It has been shown that the prevalence of valvular disease (diagnosed by echocardiography) in SLE can be more than 50% [4–6].

Libman-Sacks (LS) endocarditis was first described in 1924 by Libman and Sacks, as the cardiac manifestation in SLE and antiphospholipid antibody syndrome (APS) [1, 5, 7]. It is noninfectious verrucous vegetative lesions that may clinically mimic infective endocarditis. Involvement of all four valves could be seen in SLE patients. It has a preference on the left side of the heart, mainly on the mitral valve, followed by the aortic valve, but it also can be seen on the papillary muscle and chordae tendineae, left atrial wall, left ventricular septum, and aortic wall. Mitral regurgitation and aortic insufficiency are the prominent functional abnormality, although stenotic aortic and mitral valve have been rarely reported. In right-sided valves, thickening and vegetation are more seen in tricuspid valve than pulmonary and there is a low prevalence of pulmonary hypertension in SLE patients [8, 9]. The valve involvement stimulates a broad spectrum of presentations. It is typically mild and asymptomatic but can lead to fulminant presentation such as superimposed bacterial endocarditis, thromboembolic events, and congestive heart failure [1, 2, 5, 7]. Echocardiography remains the best imaging modality for early and accurate diagnosis and helps to avoid misdiagnosis (papillary fibroelastoma and infective endocarditis). The definitive diagnosis can be achieved by histopathologic examination of the valve [1–5]. It consists of fibrin deposits, fibroblastic organization, neovascularisation, immune complexes, and infiltration of mononuclear cells [1, 10]. In the healed form, there is a fibrous plaque with focal calcification but marked scarring and valve deformity is seen in the presence of extensive involvement in the other extreme of the disease, which may require surgical treatment (repair/replacement). It was suggested that the presence of LS endocarditis has correlation to longer duration of disease, higher disease activity, and increased risk of thrombotic
events [1, 2, 7, 11]. However, heart failure (due to mitral regurgitation) as the first manifestation of the disease was reported too [12].

Data regarding the outcome of mitral valve surgery in patients with SLE are limited and generally restricted to case reports or small series. In this study we report a case of mitral valve replacement for severe stenosis caused by LS endocarditis. In addition, we provide a systematic review of the literature for surgical consideration and highlight some important concerns that need to be addressed.

2. Case Presentation

A 17-year-old girl presented at our institution with longstanding SLE. The first presentation was macroscopic hematuria when she was 2 years old. The definitive diagnosis was made by renal biopsy 9 years ago and she has been treated since then. The patient was admitted with progressive exertional dyspnea and unexplained tachycardia of 2-month duration. Ten months prior to this episode she had developed central facial paresis and pancytopenia. She had no history of rheumatic fever. Echocardiography revealed severe mitral stenosis with thickened mitral valve leaflets, small vegetations on the posterior mitral valve leaflet, and chordae, with no pleural and pericardial effusion.

Her medications were CellCept (mycophenolate mofetil, 500 mg/12 h) and oral steroid (prednisolone, 7.5 mg/daily). Admission laboratory tests revealed normal serum chemistry. The surgery was performed using standard cardiopulmonary bypass with cardioplegic arrest and intermittent cold bloody cardioplegia. Heparin was administered at initial dose of 300 IU/kg and additional dose was repeated to maintain activated clotting time >450 seconds. There were no dense pericardial and pleural adhesions. Both the anterior and posterior mitral leaflets were thickened, fibrotic with diffuse focal vegetations, but the annulus was intact and normal. Vegetations extended to the subvalvular apparatus. The bands of tissue involved most of the chordae of the posterior mitral leaflet. Therefore, mitral valve repair was not considered feasible and appropriate. The mitral valve was replaced with a 23 mm St. Jude aortic mechanical prosthesis in a reversed direction.

Pathological examination of the excised mitral valve leaflets showed fibrosis, neovascularization, vegetation with fibrin-platelet thrombi, and inflammatory cell infiltration which was consistent with LS endocarditis. The attached chordae tendineae were partially fused and myxomatous with focal fibrosis. The patient's recovery from surgery was uneventful and she was discharged on the seventh postoperative day.

3. Search Strategy

We reviewed the literature on mitral valve surgery in the SLE setting ± APS. Although valve thickening and vegetation (LS endocarditis) were described in SLE patients at first, it is the most common finding in APS patients too [1, 5, 27, 31]. Because of higher prevalence of valve involvement in APS secondary to SLE (more than 50%), this association is included in this search [1, 7, 17].

Medline and Google Scholar from 1970 through December 2013 used the PubMed interface: (title/abstract) systemic lupus erythematosus OR SLE OR Libman-Sacks endocarditis AND mitral valve surgery OR mitral valve replacement OR mitral valve involvement, without language restriction. We selected all relevant papers that related to mitral valve surgery (repair or replacement, due to regurgitation and/or stenosis, and ± other cardiac valve involvement) in the context of SLE and/or APS secondary to SLE. There were 19 case reports and 3 review articles identified in the world medical literature [5, 16, 17]. They were reviewed to suggest important applicable point for future use with surgically oriented option. Bouma et al. had selected only isolated mitral regurgitation (MR) caused by LS endocarditis in English journals in their systematic review [5]. We included all mitral valve pathology (regurgitation, stenosis, or both) that needed surgery in SLE patients ± APS, without language limitation. Gorki et al. reviewed mitral and aortic valve involvement in APS patients ± SLE [17]. Due to our focus on SLE disease, we selected SLE patients ± APS with mitral valve pathology. Hakim et al. appraised mitral surgery in SLE patients till 2001 [16].

There were 47 cases of pure MR and 17 cases of mitral stenosis (MS) reported in SLE patients with surgical treatment in the literature. Valve pathology was not defined in 15 patients. Tables 1 and 2 show that the surgical options for MS were less frequent in recent years. It is unknown whether advanced medical treatment and closer control would decrease grade of stenosis requiring surgery. Also five SLE patients that had both MS and MR were reported. This combination is more frequent in SLE with secondary APS. Table 1 displays 18 cases of mitral repair; 4 of them needed reoperation during short follow-up. Mitral stenosis was the dominant pathology in these patients and valve calcification was the main cause of reoperation and valve replacement. None of them had APS association. It seems that the success rate of mitral valve repair in SLE patients is less than other etiologies and surgical repair for MS probably needs more reoperation than MR valves.

4. Discussion

According to the literature, the prevalence of cardiovascular involvement in patients with SLE has been estimated to be more than 50% [1, 4, 5, 16, 17]. It was shown that the left-sided heart valves are affected most commonly. The most frequently involved valve is the mitral valve followed by the aortic valve and regurgitation represents the predominant abnormality [1, 2, 4, 6, 9]. The mitral valve involvement in patients with SLE has been categorized as leaflet thickening, vegetations (LS endocarditis), regurgitation, and valve stenosis [1, 2, 5, 7–11, 16, 32]. Mitral stenosis is the least valvular manifestation (<5%) and is frequently associated with MR [4, 9].

It is thought that immunologic insults (infiltration of inflammatory cells and immune complex deposition) play principal role. There is the sequence of insult events from formation of fibrin-platelet thrombi, its organization, fibrosis,
| First author | Published Year | Sex/Age | Disease | Mitral Pathology | Type of Surgery | Outcome |
|--------------|----------------|---------|---------|------------------|-----------------|---------|
| Benotti      | 1984           | f/16    | SLE     | MR, AI           | Repair of anterior mitral leaflet, AVR with biologic valve | 6y follow-up remained significant MR |
| Nishimura    | 1989           | f/24    | SLE     | MS               | MVR after 2 times OMVC | Mediastinal hemorrhage on 21st day postoperatively, died of septicemia |
| Pomerantzeff | 1999           | f/48    | SLE     | MS               | OMVC, after 6m MVR with biologic valve | 7y follow-up |
| Hakim        | 2001           | f/34    | SLE     | MR               | Repair, redo MVR, biologic valve | Developed CHF 1y follow-up |
| Hakim        | 2001           | f/28    | SLE     | MR               | Repair | Recurred MR 12m follow-up |
| Gorki        | 2008           | f/27    | SLE + APS | MS, MR | OMVC, Kay’s annuloplasty, Quadrangular resection + annuloplasty ring, CABG | 18m follow-up NR |
| Gorki        | 2008           | f/53    | SLE + APS | MR, CAD | OMVC, Kay’s annuloplasty, Quadrangular resection + annuloplasty ring, CABG | 18m follow-up NR |
| Bouma        | 2010           | f/17    | SLE     | MR               | Posterior leaflet enlargement and annuloplasty, MVR with mechanical valve | 12m follow-up |
| Bouma        | 2010           | f/54    | SLE     | MR               | Repair | Developed MR after 29 months MVR, mechanical valve | 5y follow-up |
| Bouma        | 2010           | m/23    | SLE     | MR               | Repair | Quadrangular resection of posterior leaflet and annuloplasty ring | 3y follow-up |
| Bouma        | 2010           | m/58    | SLE + APS | MR       | Valvuloplasty and annuloplasty | NR |
| Bouma        | 2010           | m/49    | SLE     | MR               | Quadrangular resection of posterior leaflet and annuloplasty ring | Trace MR in 11y follow-up |
| Perier       | 2011           | f/NR   | SLE + APS | MR               | Vegetation removal, ring annuloplasty | NR |
| Tanawuttiwat | 2011           | f/22    | SLE     | MR, AS           | Vegetation removal, ring annuloplasty | VF and TIA due to embolic event, 2y follow-up |
| Bourr´e-Tessier | 2011        | f/14    | SLE     | MR               | Wedge resection of anterior leaflet, commissuroplasty, posterior leaflet commissuroplasty | 10y follow-up |
| Roshanali    | 2012           | f/17    | SLE + RF | MS + MR | Ring annuloplasty and anterior leaflet augmentation with autologous pericardium | Need for MVR due to valve calcification in short follow-up |

**Abbreviations:** AI: aortic insufficiency, APS: antiphospholipid syndrome, AS: aortic stenosis, AVR: aortic valve replacement, CABG: coronary artery bypass graft, CAD: coronary artery disease, CHF: congestive heart failure, f: female, m: male, m: month(s), MR: mitral regurgitation, MS: mitral stenosis, MVR: mitral valve replacement, NR: not reported, OMVC: open mitral valvectomy, RF: rheumatoid arthritis, SLE: systemic lupus erythematosus, TIA: transient ischemic attack, VF: ventricular fibrillation, y: year.
Table 2: Reported cases of mitral valve replacement in SLE patients.

| First author | Year | Age/sex | Disease | Mitral pathology | Type of surgery | Outcome |
|--------------|------|---------|---------|------------------|----------------|---------|
| Reilly [21]  | 1988 | f/NR    | SLE     | MS               | MVR, biologic valve | 24 m follow-up |
| Hussain [22] | 1993 | f/NR    | SLE     | MS               | MVR, mechanical valve | NR |
| Hofer [23]   | 1999 | f/NR    | SLE     | MS               | MVR, mechanical valve | Died in 3rd post-op due to cerebral hemorrhage |
| Yilmaz [24]  | 2008 | f/NR    | SLE     | MS               | MVR, mechanical valve | Died on second day due to renal failure |
| Hakim [16]   | 2001 | f/29    | SLE     | MS (calcified, thickened leaflet) | MVR, mechanical valve | PA |
| Hakim [16]   | 2001 | m/59    | SLE     | MS (thickened, fibrotic, and scarring) | AVR, MVR, and mechanical valve | NP |
| Hakim [16]   | 2001 | f/37    | SLE     | MS (thickened, fibrotic) | MVR, mechanical valve | NP |
| Hakim [16]   | 2001 | m/45    | SLE     | MS (thickened, fibrotic) | MVR, mechanical valve | NP |
| Hakim [16]   | 2001 | f/31    | SLE     | MS (thickened, fibrotic) | MVR, mechanical valve | NP |
| Hakim [16]   | 2001 | f/16    | SLE     | MR (Libman-Sacks endocarditis) | MVR | NP |
| Hakim [16]   | 2001 | m/30    | SLE     | MR, AI (ruptured chordae, muciform degeneration) | AVR/MVR, mechanical valve | NP |
| Hakim [16]   | 2001 | f/40    | SLE + APS | MS | MVR, biologic valve | 36 m follow-up |
| Hakim [16]   | 2001 | f/49    | SLE + APS | MR (Libman-Sacks endocarditis) | MVR, AVR, NR | NR |
| Hakim [16]   | 2001 | f/38    | SLE     | MR (Libman-Sacks endocarditis) | MVR, mechanical valve | NP |
| Hakim [16]   | 2001 | f/66    | SLE     | MS (calcified, thick) | MVR, NR | NR |
| Hakim [16]   | 2001 | f/40    | SLE     | MR (prolapsed leaflet) | MVR, NR | NR |
| Hakim [16]   | 2001 | f/25    | SLE     | MR (prolapsed leaflet, endocarditis) | AVR/MVR, NR | NR |
| Hakim [16]   | 2001 | f/16    | SLE     | MR (fibrotic, calcified, thickened valve and chordate) | MVR | NP |
| Hakim [16]   | 2001 | m/4     | SLE     | MS (thickened, fibrotic ring and chordae) | MVR | Died after 3 years |
| Hakim [16]   | 2001 | m/44    | SLE     | MR (fibrotic, ruptured chordae) | MVR, NR | NP |
| Hakim [16]   | 2001 | f/39    | SLE + APS | MR (chordae rupture) | MVR, biologic valve | 48 m follow-up |
| Hakim [16]   | 2001 | f/17    | SLE     | MR (fused chordae, thickened valve) | MVR, mechanical valve | NR |
| Hakim [16]   | 2001 | f/40    | SLE     | MR (dilated valve ring, fibrotic) | MVR, mechanical valve | Mediastinitis |
| Hakim [16]   | 2001 | f/45    | SLE     | MR (fibrotic, calcified, thick, and retracted) | MVR, mechanical valve | NR |
| Hakim [16]   | 2001 | f/23    | SLE     | MR (fibrotic, calcified, thickened valve) | MVR, mechanical valve | 12 m follow-up |
| Hakim [16]   | 2001 | f/45    | SLE     | MR, AI (retracted, thick valve) | MVR, AVR, and mechanical valve | 7 y follow-up |
| Hakim [16]   | 2001 | f/64    | SLE     | MR (pink leaflet, fragile chordae) | MVR, mechanical valve | 3 y follow-up |
| First author | Year | Age/sex | Disease | Mitral pathology | Type of surgery | Outcome |
|-------------|------|---------|---------|-----------------|-----------------|---------|
| Hakim [16]  | 2001 | f/36    | SLE+APS | NR              | MVR, NP         | Died at 1 year, hemorrhagic CVA |
| Hasegawa [25]| 2001 | f/51    | SLE+APS | MS              | MVR, NR         | NR      |
| Lan [4]     | 2005 | m/22    | SLE     | MR              | MVR, NR         | NR      |
| Gorki [17]  | 2008 | f/42    | SLE+APS | NR              | MVR, mechanical valve | NR     |
| Gorki [17]  | 2008 | f/29    | SLE+APS | MR              | MVR, mechanical valve | 24 m follow-up |
| Gorki [17]  | 2008 | f/41    | SLE+APS | MR, MS          | MVR, NR         | 48 m follow-up |
| Gorki [17]  | 2008 | f/45    | SLE+APS | NR              | MVR, NR         | NR      |
| Gorki [17]  | 2008 | f/39    | SLE+APS | NR              | MVR, biologic valve | 108 m follow-up |
| Gorki [17]  | 2008 | f/46    | SLE+APS | NR              | MVR, mechanical valve | NR     |
| Gorki [17]  | 2008 | f/31    | SLE+APS | NR              | MVR, mechanical valve | 2 m follow-up |
| Gorki [17]  | 2008 | f/48    | SLE+APS | NR              | MVR, mechanical valve, TV repair | Death in 1st day |
| Gorki [17]  | 2008 | f/43    | SLE+APS | NR              | MVR, mechanical valve, TV repair | Death in 22nd day |
| Gorki [17]  | 2008 | f/38    | SLE+APS | NR              | MVR, mechanical valve | 32 m follow-up |
| Gorki [17]  | 2008 | f/51    | SLE+APS | NR              | MVR, mechanical valve | 33 m follow-up |
| Gorki [17]  | 2008 | f/54    | SLE+APS | NR              | MVR, mechanical valve | 6 m follow-up |
| Gorki [17]  | 2008 | f/31    | SLE+APS | MR              | MVR, mechanical valve | 2 m follow-up |
| Bouma [5]   | 2010 | f/22    | SLE     | MR (ruptured chordae, thickened valve) | MVR, biologic valve | Alive 2 months post-op |
| Bouma [5]   | 2010 | f/18    | SLE     | MR, MS (ruptured chordae, calcified, thickened fibrotic, scarring) | MVR, biologic valve | Alive 4 months post-op |
| Bouma [5]   | 2010 | f/27    | SLE     | MR (ruptured chordae) | MVR, biologic valve | NP |
| Bouma [5]   | 2010 | m/51    | SLE     | MR (ruptured chordae) | MVR, biologic valve | NP |
| Bouma [5]   | 2010 | f/20    | SLE     | MR (fused chordae) | MVR, mechanical valve | CVA 17 months later |
| Bouma [5]   | 2010 | m/43    | SLE     | MR (retracted, fused valve) | MVR, mechanical valve | 4 y follow-up |
| Bouma [5]   | 2010 | f/54    | SLE     | AL, MR (central perforation, vegetation) | AVR/MVR, biologic valve | 26 m follow-up |
| Bouma [5]   | 2010 | f/22    | SLE     | MR (inflammatory, fibrinoid necrosis) | MVR, biologic valve | NR died intraoperatively |
| Bouma [5]   | 2010 | f/67    | SLE     | MR (fibrotic, calcified) | MVR, mechanical valve | |
| Bouma [5]   | 2010 | m/34    | SLE     | MS, AI (fibrotic, calcified, and thick) | MVR, biologic valve | 30 m follow-up |
| Bouma [5]   | 2010 | m/37    | SLE+APS | MR, AI | MVR, AVR, and biologic valve | Recurrent A-V fistula died 1 m after redoing MVR |
| Bouma [5]   | 2010 | f/49    | SLE+APS | NR | MVR, NR | |
| Bouma [5]   | 2010 | f/54    | SLE+APS | MR | MVR, mechanical valve | Death 9 m postoperative |
| Bouma [5]   | 2010 | f/44    | SLE     | MR | MVR, mechanical valve | 6 m follow-up |
| Bouma [5]   | 2010 | f/57    | SLE+APS | MR | MVR, mechanical valve | MI in 2nd day, 2 m follow-up |
| Bouma [5]   | 2010 | f/28    | SLE+APS | MR | MVR, mechanical valve | |
| Kondo [26]  | 2010 | f/56    | SLE + secondary amyloidosis | MR | MVR, mechanical valve | New vegetation on replaced valve and multisystem failure caused her death 3 m later |
| Bouma [5]   | 2010 | m/56    | SLE     | MR | MVR, mechanical valve | 18 m follow-up |
| Coll [27]   | 2010 | m/37    | SLE+APS | MR | MVR, mechanical valve | Died on 8th day postoperative to massive ischemic stroke |
| Coll [27]   | 2010 | f/32    | SLE+APS | MR | MVR, biologic valve | 5-year follow-up |
| First author | Year | Age/sex | Disease | Mitral pathology | Type of surgery | Outcome |
|--------------|------|---------|---------|------------------|----------------|---------|
| Morisaki [28] | 2012 | f/41 | SLE + APS | MS, MR | MVR | NR |
| Nowicka [12]  | 2012 | f/24 | SLE | MR | MVR, mechanical valve | NR |
| Soeiro [29]  | 2012 | f/45 | SLE + APS | MS, early structural valve deterioration, MVR (biologic valve) due to endocarditis 9 y ago | MVR, mechanical valve | NR |
| El-Mohamady [30] | 2013 | f/30 | SLE + APS | MS, history of acute myocardial infarction and cerebral thromboembolic events | MVR, biologic valve | NR |

A1: aortic insufficiency, APS: antiphospholipid syndrome, AS: aortic stenosis, AVR: aortic valve replacement, CABG: coronary artery bypass graft, CAD: coronary artery disease, CHF: congestive heart failure, CVA: cerebrovascular accident f: female, m: male, m: month(s), MR: mitral regurgitation, MS: mitral stenosis, MVR: mitral valve replacement, NR: not reported, OMVC: open mitral valve commissurotomy, RF: rheumatic fever, SLE: systemic lupus erythematosus, TIA: transient ischemic attack, TV: tricuspid valve, VF: ventricular fibrillation, and y: year.
edema, diffuse thickening, inflammatory changes (acute, chronic, and recurrent inflammation), distortion, and scarring to valve dysfunction [1, 2, 5, 7].

4.1. Medical Treatment. Treatment of valvular manifestation of SLE depends on the type and severity of involvement. Because of the lack of large systematic studies, treatment options remain a challenge.

Important hemodynamic valvular dysfunction can be managed with conservative treatment (including ACE inhibitors, beta blockers, diuretics, immunosuppression, anticoagulation, and endocarditis prophylaxis) in some patients.

There is controversy about the place of steroids in this setting. Some investigators have suggested that the introduction of corticosteroid as the cornerstone of SLE treatment may decrease the frequency of symptoms and disease activity [4, 7, 17, 33]. Steroids do not prevent LS endocarditis, although they facilitate healing of lesions over time by decreasing the inflammation and valve damage. However, they can promote fibrosis, scarring (shortening of leaflet, chordae, and valve inflammation and valve damage). However, they can promote fibrosis, scarring (shortening of leaflet, chordae, and valve deformation), and thickening, resulting in additional damage and valve dysfunction [1, 4, 5, 7, 32]. There was a case report of rapid appearance of severe mitral regurgitation (by sequential echocardiography) in this SLE patient who received high dose corticosteroid therapy for acute relapse of disease [34].

4.2. Valve Repair. Valve surgery may be required if severe symptomatic valvular dysfunction persists [5, 7]. There is no definite consensus about surgical procedure: repair versus replacement and mechanical versus biologic valve [5, 16, 17, 32]. In current cardiac surgery, there is no doubt about the superiority of mitral valve repair versus replacement whenever possible for most cases of mitral regurgitation by different etiologies [5]. It is associated with better preservation of left ventricular function and fewer valve related complications [3].

It is suggested that mitral reconstruction might be a preferable approach as the need for anticoagulant medication is avoided. Moreover in the presence of obligatory prolonged steroid use in young patients who usually experience renal failure and undergoing hemodialysis, anticoagulation may trigger higher risk [16], especially in young females, who are likely to become pregnant in the future [5, 7].

It is believed that mitral valve repair can be justified in specific patients. If SLE status has been fairly stable with medical management and intraoperative examination shows absence of severe structural damage (with only localized and limited abnormalities), if repair seems possible and practical, then mitral valve repair is the preferred surgical option [3, 5, 16, 17]. If there is extensive fibrous network relating to papillary muscles, it may prohibit durable repair. It was reported that debridement and valve preservation would be adequate operation in the patients who had thromboembolic events from LS vegetation in the presence of normal valve structure and function [17]. In disagreement with this policy, there are case reports that show that correction of the pathologic insult for mitral regurgitation does not modify the nature of disease and valve thickening will progress; calcification and fibrosis lead to rapid recurrence of regurgitation after repair with additional risk of subsequent reoperation for replacement [4, 5, 16].

It is suggested that, in the association of SLE with hypercoagulable state like APS, repair is better option when possible [7]. APS itself increases the risk of thromboembolic complications and the need for higher intensity oral anticoagulation therapy (INR ≥ 3).

4.3. Valve Replacement. Valve replacement has been suggested as the choice technique because valve tissue resection en bloc will definitely prevent recurrence [35]. Mitral valve replacement with subvalvular apparatus preservation may be a good surgical alternative whenever possible [5]. But if there is fused, thick, and huge chordae and papillary muscle, complete resection is recommended as its preservation can prevent free movement of mechanical valve leaflets. Heparin should be initiated immediately after the operation to prevent thrombosis [25].

In the subject of mitral valve replacement, prosthetic valve selection is highly individualized based on age, APS association, and other conditions such as situations which need a prolonged anticoagulation use, like atrial fibrillation [3, 5, 16].

Although successful placement of biologic valve has been reported, massive thrombosis, leaflet perforation, valvulitis, and rapid mineralization were described in this situation [5, 16, 17]. In addition cases with 8 years of follow-up of biologic valve were reported; it was mentioned that in two reported long term results of biologic valve replacements were done due to pannus formation and not due to valve failure in this setting [17].

SLE associated renal failure can accelerate deterioration of the structural valve secondary to abnormal calcium and phosphate metabolism [5, 16, 18]. If renal involvement is prominent feature in SLE patient, use of mechanical valve provides better result although the risk of thromboembolic events remains. However, in patients who are at low risk with anticoagulation and high risk for biologic valve calcification, mechanical valve replacement is recommended [5].

In patients with bleeding abnormalities the superiority of biologic valves over mechanical valves is clear. If there is association of APS in SLE patient, thrombotic manifestation on the valve because of hypercoagulopathy state is prominent. It was described that thromboembolic events could occur even with a target INR of 3-4 in these patients [17]. These patients undergoing valve surgery are at higher risk of thrombotic complications and biologic valve was recommended [5, 7, 16, 17, 27].

The need for lifelong anticoagulation in mechanical valve and the risk of hemorrhagic and thromboembolic events of them despite their prolonged durability must be balanced with hypercoagulable state in APS patients and the risk of immunologic deterioration of the biologic valve (rapid calcification, valvulitis, and leaflet perforation).
4.4. Mitral Stenosis versus Regurgitation. It seems that SEL patients in the setting of stenosis had more adverse outcome in comparison with regurgitation. There were case reports of these patients with valve repair or replacement that had needed reoperation due to mitral restenosis [14, 15, 36]. It looks that disease progress is more prominent in stenotic valve and suggested aggressive therapy to remove vegetative tissue in the first operation as much as possible in order to prevent local extension of it that produce restenosis or malfunction of prosthetic valve. These patients may need a higher dose of steroids and immunosuppressive drugs to control the disease. Regular echocardiography and valve assessment is recommended in these patients in spite of being asymptomatic clinically. On the other hand there are reports that show mitral regurgitation symptoms and grade could be controlled frequently by medical management [16, 31, 37].

5. Conclusion

The experience with mitral valve surgery in SLE patients is limited. Review of the literature has shown that outcome is good in most patients who have undergone surgery but association of APS has negative impact on outcome. If there is localized abnormality in normal structure and function of mitral valve in relatively stable and controlled SLE patient, valve repair is a better choice. In patients with association of APS, due to increased risk of thrombotic events, biologic valve is advised. In active lupus nephritis and abnormal calcium metabolism, mechanical valve is a better option. In patients who are at low risk with anticoagulant, mechanical valve is suggested.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors wish to express their gratitude to S. M. Mirhosseini for reviewing the paper.

References

[1] J. Bourrè-Tessier, T. Huynh, A. E. Clarke et al., “Features associated with cardiac abnormalities in systemic lupus erythematosus,” Lupus, vol. 20, no. 14, pp. 1518–1525, 2011.

[2] A. Amoroso, F. Cacciapaglia, S. De Castro et al., “The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement,” Clinical and Experimental Rheumatology, vol. 24, no. 3, pp. 287–294, 2006.

[3] C. M. Vassileva, M. N. Swong, T. M. Boley, S. J. Markwell, and S. R. Hazelrigg, “Influence of systemic lupus erythematosus on procedure selection and outcomes of patients undergoing isolated mitral valve surgery,” Journal of Cardiac Surgery, vol. 27, no. 1, pp. 29–33, 2012.

[4] L. W. Lan, C. Tsai, and C. J. Hsu, “The valvular involvement of lupus: congestive heart failure can be the presenting feature of systemic lupus erythematosus,” Acta Cardiologica Sinica, vol. 21, no. 2, pp. 111–115, 2005.

[5] W. Bouma, T. J. Klinkenberg, I. C. C. van der Horst et al., “Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature,” Journal of Cardiothoracic Surgery, vol. 5, no. 1, article 13, 2010.

[6] C.-H. Lin, M.-L. Lee, and R.-B. Hsu, “Cardiac surgery in patients with systemic lupus erythematosus,” Interactive Cardiovascular and Thoracic Surgery, vol. 4, no. 6, pp. 618–621, 2005.

[7] E. Ferreira, P. M. Bettencourt, and L. M. Moura, “Valvular lesions in patients with systemic lupus erythematosus and antiphospholipid syndrome: An old disease but a persistent challenge,” Revista Portuguesa de Cardiologia, vol. 31, no. 4, pp. 295–299, 2012.

[8] G. Ruiz-Irastorza, M. Garmendia, I. Villar, M. Egurbide, and C. Aguirre, “Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy,” Autoimmunity Reviews, vol. 12, no. 3, pp. 410–415, 2013.

[9] N. E. Doherty and R. J. Siegel, “Cardiovascular manifestations of systemic lupus erythematosus,” The American Heart Journal, vol. 110, no. 6, pp. 1257–1265, 1985.

[10] M. Hojinik, J. George, L. Ziporen, and Y. Shoenfeld, “Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome,” Circulation, vol. 93, no. 8, pp. 1579–1587, 1996.

[11] I. Moyssakis, M. G. Tektonidou, V. A. Vasiliiou, M. Samarkos, V. Votetas, and H. M. Moutsopoulos, “Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution,” American Journal of Medicine, vol. 120, no. 7, pp. 636–642, 2007.

[12] A. Nowicka, A. Piatkowska, W. Biegalski et al., “Severe mitral regurgitation as the first symptom of systemic lupus erythematosus in a young woman required mitral valve replacement,” Kardiologia Polska, vol. 70, no. 4, pp. 421–423, 2012.

[13] J. R. Benotti, L. R. Sataline, L. J. Sloss, and L. H. Cohn, “Aortic and mitral insufficiency complicating fulminant systemic lupus erythematosus,” Chest, vol. 86, no. 1, pp. 140–143, 1984.

[14] M. Nishimura, T. Hiranaka, O. Kuroda, J. Kobayashi, and K. Onishi, “Acute massive mediastinal hemorrhage three weeks after mitral valve replacement in a patient with systemic lupus erythematosus,” Journal of the Japanese Association for Thoracic Surgery, vol. 37, no. 11, pp. 2371–2377, 1989.

[15] P. M. A. Pomerantzeff, J. D. H. Corrêa, C. M. de Almeida Brandão, R. V. C. de Assis, and A. D. Jatene, “Mitral restenosis in the early postoperative period of a patient with systemic lupus erythematosus,” Arquivos Brasileiros de Cardiologia, vol. 72, no. 4, pp. 485–486, 1999.

[16] J. P. Hakim, A. Mehta, A. C. Jain, and G. F. Murray, “Mitral valve replacement and repair: report of 5 patients with systemic lupus erythematosus,” Texas Heart Institute Journal, vol. 28, no. 1, pp. 47–52, 2001.

[17] H. Gorki, V. Malinovski, and R. D. L. Stanbridge, “The antiphospholipid syndrome and heart valve surgery,” European Journal of Cardio-Thoracic Surgery, vol. 33, no. 2, pp. 168–181, 2008.

[18] P. Perier, M. Jeserich, M. Vieth, K. Pohle, W. Hohenberger, and A. Diegeler, “Mitral valve reconstruction in a patient with Libman-Sacks endocarditis: a case report,” The Journal of Heart Valve Disease, vol. 20, no. 1, pp. 103–106, 2011.

[19] T. Tanawuttiwat, M. Dia, T. Hanif, and M. Mihaiescu, “Double-valve libman-sacks endocarditis causing ventricular fibrillation cardiac arrest,” Texas Heart Institute Journal, vol. 38, no. 3, pp. 295–297, 2011.
[20] F. Roshanali, S. Oraii, and H. Mandegar, "Outcome of mitral valve repair in a patient with systemic lupus erythematosus," British Medical Journal, 2012.

[21] P. A. Reilly, P. J. Maddison, R. D. Thomas, P. A. Poole-Wilson, and J. G. Bennett, "Mitrail stenosis in systemic lupus erythematosus. Successful management by mitral valve replacement," European Journal of Cardio-Thoracic Surgery, vol. 2, no. 5, pp. 377–379, 1988.

[22] R. Hussain and M. C. Neligan, "Systemic lupus erythematosus a rare cause of mitral stenosis," The Thoracic and Cardiovascular Surgeon, vol. 41, no. 2, pp. 125–126, 1993.

[23] E. Hoffer, M. Itoua, M. Radermecker, and L. Piéard, "Stenosis of a mechanical mitral prosthetic valve in a patient with systemic lupus erythematosus," Acta Cardiologica, vol. 55, no. 1, pp. 49–51, 1999.

[24] B. A. Yilmaz, N. Düzgün, T. Mete et al., "AA amyloidosis associated with systemic lupus erythematosus: impact on clinical course and outcome," Rheumatology International, vol. 28, no. 4, pp. 367–370, 2008.

[25] R. Hasegawa, H. Kitahara, K. Watanabe, H. Kuroda, and J. Amano, "Mitrail stenosis and regurgitation with systemic lupus erythematosus and antiphospholipid antibody syndrome," The Japanese Journal of Thoracic and Cardiovascular Surgery, vol. 49, no. 12, pp. 711–713, 2001.

[26] H. Kondo, M. Nakayama, and H. Ishikawa, "Mitrail valve replacement for mitral valve stenosis and insufficiency in a patient with antiphospholipid syndrome and systemic lupus erythematosus; report of a case," The Japanese journal of thoracic surgery, vol. 63, no. 13, pp. 1173–1175, 2010.

[27] A. Colli, C. A. Mestres, G. Espinosa et al., "Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases," European Journal of Cardio-Thoracic Surgery, vol. 37, no. 1, pp. 154–158, 2010.

[28] A. Morisaki, H. Hirai, Y. Sasaki et al., "Mitrail bioprosthetic valve stenosis in a patient with antiphospholipid antibody syndrome and systemic lupus erythematosus," General Thoracic and Cardiovascular Surgery, vol. 60, no. 12, pp. 822–826, 2012.

[29] A. D. M. Soeiro, M. C. F. de Almeida, T. A. D. Accorsi, G. S. Spina, C. V. Serrano Jr., and F. Tarasoutchi, "Association between immunological diseases and their similar clinical manifestations," Arquivos Brasileiros de Cardiologia, vol. 98, no. 2, pp. e28–e31, 2012.

[30] H. S. El-Mohamady, "Systemic lupus erythematosus; its implication in cardiac surgery: Institutional case report," Journal of the Saudi Heart Association, vol. 25, no. 2, pp. 130–131, 2013.

[31] A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld, "Heart involvement in systemic lupus erythematosus, antiphospholipid syndrome and neonatal lupus," Rheumatology, vol. 45, 4, pp. iv8–iv13, 2006.

[32] J. Fernández-Dueñas, A. López-Granados, D. Mesa-Rubio, J. Ariza-Cañete, M. Gallo-Martin, and M. Concha-Ruíz, "Severe mitral regurgitation in Libman-Sacks endocarditis. Conservative surgery," Revista Espanola de Cardiologia, vol. 58, no. 9, pp. 1118–1120, 2005.

[33] J. A. Kohler Sr. and A. R. Ellis, "Libman-Sacks endocarditis in pediatric patient with systemic lupus erythematosus," Pediatric Cardiology, vol. 33, no. 8, pp. 1466–1468, 2012.

[34] R. Hoffman, H. Lethen, U. Zunker, F. A. Schondube, N. Maurin, and H.-G. Sieberth, "Rapid appearance of severe mitral regurgitation under high-dosage corticosteroid therapy in a patient with systemic lupus erythematosus," European Heart Journal, vol. 15, no. 1, pp. 138–139, 1994.